Skip Over Navigation Links

Research

BrIDGs Application Scoring Matrix

Submitted research applications will be reviewed for scientific merit and technical feasibility. The following scoring matrix will be used by reviewers to evaluate scientific merit. Although it is not a scored criterion, reviewers will also consider the quality of the intellectual property related to the proposed agent.

 Score 1-3
High Score
Score 4-6
Average Score
Score 7-9
Poor Score
Strength of Current Data Package (40%)

High quality in the relevant areas:

  • Medicinal Chemistry
  • ADME
  • PK/PD
  • Toxicology
  • In vivo models
  • Secondary and tertiary assays
  • Formulation
  • Chemical Manufacturing and Controls (CMC) - small molecules
  • Expression/Purification - Biologics

High quality in some of the relevant areas and medium quality in other relevant areas:

  • Medicinal Chemistry
  • ADME
  • PK/PD
  • Toxicology
  • In vivo models
  • Secondary and tertiary assays
  • Formulation
  • Chemical Manufacturing and Controls (CMC) - small molecules
  • Expression/Purification - Biologics

Medium or marginal quality in the relevant areas

  • Medicinal Chemistry
  • ADME
  • PK/PD
  • Toxicology
  • In vivo models
  • Secondary and tertiary assays
  • Formulation
  • Chemical Manufacturing and Controls (CMC) - small molecules
  • Expression/Purification - Biologics
Target and Therapeutic Validation (30%)Target has been validated in animal pharmacology studies as well as in humans, and there is a link to therapeutic indication.Target has been validated primarily in animal pharmacology or knock-out mouse studies.Target has been validated in primarily in vitro in animals and/or humans.
Feasibility to Reach First in Human (20%)

Have most of the following:

  • Animal models to establish efficacy
  • Clinical translation, establish clinical endpoints
  • Patient population well defined with registries
  • Market opportunity analysis

Have many of the following:

  • Animal models to establish efficacy
  • Clinical translation, establish clinical endpoints
  • Patient population well defined with registries
  • Market opportunity analysis

Have few to none of the following:

  • Animal models to establish efficacy
  • Clinical translation, establish clinical endpoints
  • Patient population well defined with registries
  • Market opportunity analysis
Medical Impact Relative to Current Standard of Care (10%)There is no current treatment for the disease or clinical outcome. Or the current standard of care has considerable disadvantages or very limited utilityThe current standard of care has potential disadvantages (resistance). Or the current standard of care has somewhat limited utilityThe current standard of care is adequate, but additional treatments are desired.

Related Links